Dr. Michael J. Smith, MD
Pediatric Infectious Disease (Pediatric Infectious Diseases Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Infectious Diseases Physician primary
KY license 41086 -
Pediatrics Physician
KY license 41086
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 9 payments worth $1,721 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,721 |
|---|
| Travel and Lodging | $1,392 |
|---|---|
| Food and Beverage | $330 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 8, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $700 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $283 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $162 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $142 |
| Merck Sharp & Dohme LLC Oct 29, 2025 | Travel and Lodging PREVYMIS · INFECTIOUS DISEASE · travel to Philadelphia, PA Company’s descriptionProvided as part of a clinical research engagement. | $106 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $574,240 in research payments for these studies, mostly to the institutions running them.
- A phase 2 randomized doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Pfizer Inc. - A Phase 1, Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Letermovir in Pediatric Kidney Transplant KT Recipients Less Than 18 Years of Age and Weighing Less Than 40 Kilograms
Merck Sharp & Dohme LLC - A phase 2 randomized partially doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine administered in healthy toddlers 12 through 15 months of age
Pfizer Inc. - A phase 1 randomized doubleblind sponsoropen study to describe the safety and tolerability of a multivalent pneumococcal conjugate vaccine in adults
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.